French cancer institute chief resigns abruptly

6 August 2006

The president of the French National Cancer Institute (INCa), David Khayat, has abruptly resigned effective from August 1, after being at the center of controversy over his administration for several months (Marketletter July 10).

After publicly announcing that an independent audit commissioned by the French ministries of health and of research had exonerated him, Mr Khayat declared in June that: "I have nothing to reproach myself for. My management is impeccable, my honor is restored!"

Assuming that Mr Khayat's successor is another cancer specialist, local media reports suggest that Dominique Maraninchi, chairman of the scientific committee of the INCa and director of the Paoli-Calmettes Institute in Marseille, is the best qualified to take over.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight